RH Earnings Recaps
Q3 2025
Nov 6, 2025
Rhythm Pharmaceuticals reported strong Q3 2025 performance, highlighted by significant growth in IMCIVREE revenue and strategic advancements in their product pipeline, positioning the company for upcoming launches.
Key takeaways
- IMCIVREE sales reached $51.3 million, marking a 10% increase in reimbursed therapy patients.
- Successful completion of a $189 million equity offering in July to strengthen the balance sheet ahead of key regulatory developments.
- Regulatory filings for hypothalamic obesity (HO) accepted by both the FDA and EMEA, with a PDUFA date set for December 20, 2025.
- Upcoming preliminary results from the Phase II trial in Prader-Willi syndrome expected by year-end, aimed at demonstrating efficacy in BMI reduction.
- Expansion of the commercial team in preparation for the HO launch, targeting an estimated 10,000 patients in the U.S. market.